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THE RELATIONSHIPS AMONG THE STIMULUS FUNCTIONS
AND THE CLINICAL EFFECTS OF METHYLPHENIDATE
IN CHILDREN DIAGNOSED WITH ADHD
Emily K. MacDonald, M.A.
Western Michigan University, 2000
Attention deficit hyperactivity disorder (ADHD) is the most commonly
diagnosed childhood psychiatric disorder in the United States. Approximately 90% of
children receiving pharmacological treatment for ADHD receive the stimulant
methylphenidate (MPH). MPH is associated with positive effects across many
behavioral domains, yet the mechanisms through which it exerts clinical effects have
not been conclusively determined. MPH produces reinforcing and subjective effects,
however it is not understood how these functions relate to clinical effects. The present
study examined the relationship among several stimulus functions and the clinical
effects of MPH. Participants were 5 children (aged 10-14) diagnosed with ADHD
who were currently receiving MPH. The reinforcing effects of MPH were assessed
using a double-blind choice procedure. Subjective effects were measured using self
report questionnaires. Clinical effects were measured using direct observations and a
behavioral rating form. Results indicated that MPH functioned as a reinforcer in 3 of
the 5 participants. Out of 30 total choices across participants (6 choices each), MPH
was chosen 18 times (60%), placebo and neither were both selected 6 times (20%).
MPH also produced variable patterns of participant-rated effects across subjects.
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INTRODUCTION
Attention deficit hyperactivity disorder (ADHD) is the most commonly
diagnosed childhood psychiatric disorder in the United States, functionally impairing
approximately 3-5% of the preadolescent population (American Psychiatric
Association [APA], 1994). ADHD is characterized by a persistent pattern of
inattention and/or impulsivity-hyperactivity that is more frequent and severe than
typically observed in individuals at comparable levels of development (AP A, 1994).
Children diagnosed with ADHD may be unable to sit still and pay attention in class,
have poor peer relations, and exhibit disruptive behavior. These behaviors can often
lead to academic, social and behavioral difficulties. To address these behavioral
problems, approximately 85-95% of individuals diagnosed with ADHD receive
psychopharmacological treatment, and approximately 90% of children receiving
medication are treated with the stimulant, methylphenidate (Ritalin®; Robison, Sclar,
Skaer & Galen, 1999; Zito et al., 2000).
Methylphenidate (MPH) has been shown to have positive effects across a
wide range of behavioral domains (for reviews, see DuPaul, Barkley, & Connor,
1998; Greenhill, 1998). These clinical effects are discussed in the following sections.
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Clinical Effects of MPH
Inappropriate/Disruptive Behaviors
ADHD is associated with a developmentally inappropriate pattern of
disruptive and maladaptive behaviors, and compared to a placebo, methylphenidate
has demonstrated short-term efficacy in reducing these problems (for reviews see
Greenhill, 1995; Jacobvitz, Srouge, Stewart, & Leffert, 1990). For example, in a
study of 40 children diagnosed with ADHD, MPH significantly decreased the
percentage of fidgety behavior, motor restlessness, teacher ratings of inattention,
overactivity and problem situations (DuPaul, Barkley, & McMurray, 1994).
Treatment with MPH is also associated with reductions in overt aggression
(e.g., Gadow, Nolan, Sverd, Sprafkin, & Paolicelli, 1990), covert aggression (e.g.,
Bukstein & Kolkso, 1998) and displays of covert antisocial behaviors such as stealing
and property destruction (e.g., Klein et al. 1997). For example, in a three year study
of 83 children, Klein et al. (1997) found that children who received MPH (average
dose 41.3 mg/day) versus placebo demonstrated reductions in antisocial behaviors
such as obscene language, attacking others, stealing and property destruction as
measured by parent, teacher and clinician ratings and direct classroom observations.
Academic Functioning
Children diagnosed with ADHD typically experience school-related
difficulties in areas of academic performance and achievement (Barkley, DuPaul, &
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McMurray, 1990). Studies have demonstrated that methylphenidate contributes to
immediate improvements in arithmetic, spelling and handwriting in children
diagnosed with ADHD (for review see DuPaul et al., 1998). For example, Stoner et
al. (1994) investigated the utility of curriculum-based measures (CBM) of math and
reading for evaluating the effects of MPH (5 mg, 10 mg, 15 mg) on the academic
performance of two students diagnosed with ADHD. The results demonstrated that
improvements were seen in these areas, with best academic performances at 15 mg
for one student and 5 mg for another student (Stoner et al., 1994).
Stimulant-induced improvements in academic productivity, teacher ratings of
academic performance and accuracy have also been found in several other studies
(e.g., DuPaul, Barkley, & McMurray, 1994; Pelham, & Milich, 1991). In a study of
76 children diagnosed with ADHD, Rapport, Denney, DuPaul, & Gardner (1994)
evaluated the effects of MPH (5, 10, 15 and 20 mg) on children's attention, academic
efficiency and teacher ratings of classroom behaviors. Children were observed in their
regular classrooms for 20 minutes, 3 days/week across a six-week period. Weekly
classroom behaviors were measured by teacher ratings every Friday. Attention was
characterized as on-task or off-task during 15-second observation intervals. Percent of
problems on a graded assignment completed, and the percent of problems answered
correctly were used as objective indices of academic functioning. Rapport et al.
(1994) found that attention, double-blind teacher ratings and academic functioning all
improved in a linear manner as a function of increasing dose of MPH. Additionally,
compared to a group of non-diagnosed peers, 76% of ADHD children demonstrated
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significantly improved or "normalized" attention, 94% showed improvements on
teacher ratings of classroom behavior, and 53% demonstrated improved academic
performance as a function of MPH treatment.

Social Functioning

The quality of social interactions between children diagnosed with ADHD and
their parents, peers and teachers is significantly improved by MPH, along with
concurrent reductions in the intensity of these interactions (e.g., Barkley, 1989;
Rapport et al., 1994).
Numerous studies have been conducted demonstrating the effectiveness of
MPH on improving mother-child interactions of children diagnosed with ADHD
(Barkley & Cunningham, 1979; Barkley, Karlsson, Strzelecki, & Murphy, 1984).
These studies have found that MPH increases children's compliance with parental
commands and enhances their responsiveness in interactions with others. For
example, Barkley et al. (1984) observed the mother-child interactions of 54
hyperactive children, aged 4-9 years, during a double-blind, drug-placebo evaluation
of MPH (0.3 and 1.0 mg/kg) in free play and task situations. Results suggest that
MPH may "normalize" the mother-child interactions of children diagnosed with
ADHD to resemble the interactions of non-diagnosed children and their mothers. In
particular, children were observed to comply with greater frequency to maternal
commands during both free play and task situations. In addition, these children
sustained task compliance for longer time intervals, and exhibited fewer off-task
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behaviors following maternal commands as a function of receiving MPH (Barkley et
al., 1984).
In addition to affecting parent-child relationships, MPH has also been
demonstrated to affect the social interactions of children diagnosed with ADHD and
their non-diagnosed peers. In particular, MPH is dose-dependently associated with
reductions in noncompliance, verbal and physical aggression, and the negative social
behaviors exhibited by children diagnosed with ADHD (e.g., Bukstein & Kolkso,
1998). For example, in a study that examined the effects of 0.3 mg/kg MPH in 34
males, aged 7-14 years, diagnosed with ADHD, MPH decreased a variety of negative
social behaviors including interrupting, swearing and teasing (Pelham, Vodde
Hamilton, Murphy, Greenstein, & Vallano, 1991). In addition, positive peer
behaviors, such as helping, sharing, saying something nice and ignoring provocation
improved as a function of age and MPH.
Mechanisms of Drug Action
Although methylphenidate is associated with a wide range of clinically
beneficial effects, the manner in which the drug exerts its effects is not clear. That is,
the specific mechanisms by which MPH alters behaviors have not been conclusively
determined. A "mechanism of action" of a drug refers to a basic process by which a
drug interacts with some variable regulating behavior to produce a change in a
particular response (Thompson & Boren, 1977). For example, a stimulant drug like
amphetamine may be said to increase productivity if the result of the drug's
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administration is an increase in response rate ofsome behavior that results in adaptive
consequences.
The behavioral mechanism ofa drug's action is likely to vary across
individuals, even for the same type ofdrug, due to the fact that different behavioral
processes are involved in maintaining the behavior ofdifferent people (Pickens,
1977). The specification ofthese drug-behavior interactions has defined the field of
behavioral pharmacology. There is a range ofdrug variables (e.g., dosage, time
course ofdrug, etc.) that can interact with a range ofbehavioral and environmental
variables (e.g., antecedent events, response topography, consequence variables, etc.)
to produce a drug effect.
For example, a drug can interact with different schedules ofreinforcement to
produce behavioral effects. Rapport, DuPaul, and Smith (1985) investigated the
effects ofdiffering doses ofMPH on operant responding under a multiple VR 5 FI
30-second reinforcement schedule in children characterized as hyperactive. The
results showed the lower doses (5, 10 mg) increased responding on a schedule that
controlled high response rate (VR 5), while having no significant effect on
responding to a schedule which controlled a low rate (FI 30). This demonstrates that
the same dose ofMPH was shown to either increase or have no effect on operant
responding, depending on whether the performance was maintained on a VR 5 or a FI
30-second schedule. Thus, the drug effects on behavior may be explained by the
interaction between the drug and the schedules ofreinforcement under which
responding is maintained.
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Before understanding how MPH interacts with behavioral and environmental
variables to produce behavioral changes, it is necessary to briefly review the
pharmacological mechanisms through which MPH is believed to exert its effects.
MPH functions pharmacologically by stimulating the release of catecholamines.
These effects are stronger in dopaminergic as compared to noradrenergic pathways,
which are also significantly affected, and the net result is an overall facilitation of
dopaminergic transmission (Kutcher, 1997). There is also a possibility that the effects
of psychostimulants, including MPH, may be mediated by serotonergic pathways.
Gainetdinov et al. (1999) examined the effects of the psychostimulants MPH, d
amphetamine, and cocaine in mice with genetically altered dopaminergic transport
systems (e.g., DAT knockouts), which resulted in behavioral problems such as
hyperactivity. Results indicated that psychostimulants (e.g. MPH) that increase
serotonergic transmission were observed to reduce hyperactivity in the mice, and that
this effect was not a result of dopaminergic activity. However, drug-induced
alterations in neurotransmission alone do not reveal how a drug results in behavioral
changes.
Despite knowledge of methylphenidate's pharmacological effects, it is
difficult to translate these effects into clinically meaningful events because behavioral
events occur at different levels of analysis and are measured in different dimensions.
The behavioral effects of drugs could be mediated by alterations in
neurotransmission, but this does not imply that all drug effects are reducible to
physiological events. This reduction would imply that the laws of physiology, per se,
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yield the principles of drug effects on behavior (see Marr, 1990 for a discussion of
reductionism). Rather, there are several variables that are said to control the effects of
drugs on behavior, such as consequences, context, drug and behavioral history,
demonstrating that drugs can be viewed as simply another environmental
manipulation, and act as reinforcing, punishing, eliciting or discriminative stimuli
(Marr, 1990). Therefore, it is important to conceptualize other factors that interact
with the drug to have an effect on the behavior of the individual.
As mentioned previously, MPH produces changes in neurotransmitter activity,
which produces changes in central nervous system functioning. This CNS change is
associated with changes in behavior that may vary based on an individual organism's
behavioral history and the prevailing environmental conditions. These changes in
behavior subsequently exert effects on the environment, thus influencing future drug
behavior interactions (Dykstra, 1992). For example, Chait, & Perry (1992)
demonstrated that instructions and previous exposure to a drug could serve as
discriminative stimuli thereby affecting behavior. Participants with a history of
marijuana use were permitted an opportunity to smoke placebo marijuana. The
participants that were informed that placebo marijuana was in fact active marijuana
self-administered more placebo marijuana and reported more drug-induced subjective
effects than the group told they might receive placebo marijuana. It is evident that
nonpharmacological factors participate in drug-environment interactions to determine
a behavioral outcome (Thompson & Boren, 1977).
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Another example of the interaction between drugs and environmental
variables is a study that demonstrated how MPH functions as an establishing
operation (EO) when administered to children diagnosed with ADHD (Northup,
Fusilier, Swanson, Roane, and Borrero, 1997). In a study of three children diagnosed
with ADHD who were receiving MPH treatment, Northup et al. (1997) determined
that MPH functioned to change the reinforcing efficacy of at least one reinforcer
class. For example, activities functioned as more potent reinforcers following MPH
administration as compared to placebo, while edibles were more effective reinforcers
when MPH was not administered. Thus, Northup et al. (1997) demonstrated that one
of the functions of MPH in producing behavioral changes is to alter the reinforcing
efficacy of other stimuli and events in the child's environment. Thus, it is important
to examine other variables that may interact with MPH to regulate behavior.
Some clinical effects are obtained and .measured in overt behavioral terms. To
explain how MPH influences the clinical effects, we should conceptualize the
mechanisms of action that influence behavioral changes of the drug. The following
sections will provide a discussion of the discriminative stimulus effects, the
participant-rated effects, and the reinforcing effects of MPH and how these
mechanisms may influence clinical outcomes.
Discriminative Stimulus Effects
Methylphenidate can function as a discriminative stimulus, which sets the
occasion for responding that is maintained by other reinforcers. In other words,
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humans and nonhumans can be taught to discriminate between methylphenidate and
placebo. This function of MPH has been demonstrated in nonhumans (Perkins,
Eckerman, & MacPhail, 1991; Wood & Emmett-Oglesby, 1988), adult humans
(Rush, Kollins, & Pazzaglia, 1998) and children (Kollins, Shapiro, Newland, &
Abramowitz, 1998).
As Kollins et al. (1998, p. 375) pointed out, "Conceptualizing MPH as a
stimulus embedded in a pattern of ongoing behavior may offer new insights into the
behavioral mechanisms of action underlying the improvements noted with this drug."
To examine whether MPH serves as a discriminative stimulus in a clinical setting,
Kollins et al. (1998) attempted to train children (aged 6-16) diagnosed with ADHD,
who had a history of stimulant use for behavioral problems, to discriminate their
usual dose of MPH (10-20 mg) from placebo. The results indicated that children
diagnosed with ADHD could learn to reliably discriminate MPH from placebo. This
study is the only demonstration in which drugs were shown to exert discriminative
stimulus effects in children and adolescents in a manner similar to adults, suggesting
that the mechanisms that mediate drug discrimination may also operate in childhood.
Likewise, this is the only study demonstrating that a drug used to treat a clinical
disorder can be discriminated by a group of individuals diagnosed with that disorder
using traditional drug discrimination procedures. This raises the possibility that there
may be a relation between discriminative stimulus effects and clinical effects. Such a
hypothesis, however, remains to be empirically verified.
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Participant-Rated Effects
Successful drug discrimination behavior predicts that a drug may produce
some subjectively described effects, although discrimination itself is not isomorphic
with such effects (Kollins & Rush, 1999; Kollins et al., 1998; Preston & Bigelow,
1991; Rush et al., 1998). Thus, it is important to also consider the participant-rated
effects of a drug in order to gain some insight into the subjective drug experience.
Methylphenidate produces significant changes in a number of participant
rated effects when compared to placebo in human adults. Studies examining the
participant-rated effects have found that MPH significantly affects scores on several
mood scales (Chait, 1994; Heishman & Henningfield, 1991; Martin, Sloan, Sapira, &
Jasinski, 1971; Roehrs, Papineau, Rosenthal, & Roth, 1999; Rush et al., 1998; Rush,
Essman, Simpson, & Baker, in press; Smith & Davis, 1977). These studies
demonstrated that MPH increased ratings on (a) four scales of the Profile of Mood
States (POMS): (1) arousal, (2) vigor, (3) tension, (4) anxiety; (b) three scales of the
Addiction Research Center Inventory (ARCI): (1) A (amphetamine scale), (2) BG
(benzedrine group; empirically-derived amphetamine sensitive scale), and (3) MBG
(morphine benzedrine group; a measure of euphoria); (c) visual analog scale ratings
of (a) "stimulated," (b) "high," (c) "anxious," (d) "talkative," (e) "euphoric," (f) "like
drug," and (g) "like to take again." In addition, MPH has been demonstrated to reduce
scores on the ARCI subscale LSD (lysergic acid diethylamide; a measure of
dysphoria) and the POMS Fatigue scale (Chait, 1994; Roehrs et al., 1999).
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However, differing results were obtained from a sample of57 cocaine
dependent patients, in which MPH produced significant increases in (a) anxiety, (b)
depression and (c) anger on the POMS; shaky/jittery on a visual analog scale; and
dysphoria on the LSD scale ofthe ARCI (Roache, Grabowski, Schmitz, Creson, &
Rhoades, 2000).
Despite these results, few studies have examined the participant-rated effects
ofmethylphenidate in children. In a series ofexperiments, Kollins et al. (1998)
studied the participant-rated effects ofMPH in children diagnosed with ADHD using
the Subjective Effects Rating Scale (SERS) which was developed for the study. The
results demonstrated that MPH did not produce reliable patterns ofparticipant-rated
effects in children diagnosed with ADHD, despite the fact that MPH was
discriminated by these children. The children's individual ratings ofsubjective effects
were highly variable. In one experiment, the only participant who exhibited
significant changes in subjective effects was also the only participant who had
significant changes in behavior as rated by caregivers (Kollins et al., 1998). These
authors suggested that this finding may be evidence for a link between clinical effects
and subjective effects.
Several variables may account for the lack ofreliable participant-rated effects.
First ofall, Kollins et al. (1998) did not use instruments that are typically used to
assess subjective effects, such as the POMS or the ARCI. Items on the SERS were
derived from three sources. First, stimulant-appropriate items from the Addiction
Research Center Inventory (ARCI: Martin et al., 1971) were selected and changed to
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an age-appropriate reading level. Secondly, items were selected from the Side Effects
Rating Scale (Barkley, 1991). Lastly, items were selected based on discussions with
clinicians experienced in working with children diagnosed with ADHD. Although
the items on the SERS may have clinical utility for assessing the effectiveness of
stimulant medication in children, the psychometric properties of this instrument are
not known.
A second explanation for the lack of participant-rated effects could be that
these children lack the verbal repertoire, the reinforcement history for identifying
drug effects or a combination of both (Kollins et al., 1998).
In another study assessing the subjective-effects of methylphenidate, Walker,
Sprague, Sleator and Ullman (1988) examined the mood reports of children
diagnosed with ADHD who were being treated with MPH. Using a version of the
POMS modified for use in pediatric populations, they examined the effects of MPH
on six factors: (1) tension-anxiety, (2) depression-dejection, (3) anger-hostility, (4)
vigor-activity, (5) fatigue-inertia, and (6) confusion-bewilderment. Results indicated a
significant reduction in "anger-hostility" related to a 0.7 mg/kg dose of MPH.
Changes in scores on the remaining scales did not reach statistical significance.
Walker et al. (1988) noted that although the POMS is considered a reliable
measurement of mood effects, the generalization of the results to all children
diagnosed with ADHD would be unwarranted for several reasons. First, the children
and parents in this study were aware of their need for therapy and were actively
seeking outpatient treatment. Again, when studying these subjective effects, it is
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important to consider the possibility that children diagnosed with ADHD may lack
the verbal repertoire necessary to accurately describe the drug's effects.
In a similar line ofresearch Bowen, Fenton and Rappaport (1991) investigated
the general feelings, knowledge and attitudes of45 children receiving stimulant
medications for ADHD. This study also compared the children's perceptions
concerning the effects oftheir medication with those oftheir parents. Their results
demonstrated that 89% ofthe children felt that the medication was helpful and would
continue to take the medication ifthe decision was theirs, and most children (78%)
liked or were indifferent to the medication despite any side effects that were
experienced. The remaining children (11%) who responded that they would stop
taking their medication ifthey could were more likely to perceive the medication as
unhelpful. Further, Bowen et al. (1991) found that three variables (1) embarrassment
about taking medication, (2) sleeping difficulties, and (3) type ofmedication were
able to predict whether a child liked or disliked taking their medication.
Reinforcing Effects ofMethylphenidate
Most researchers agree that there is a strong relationship between the
participant-rated effects and the reinforcing effects ofmethylphenidate and other
drugs. Thus, one might predict that drugs which serve as reinforcing stimuli in
animals should produce euphoria in humans (Schuster, Fischman, & Johanson, 1981).
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Nonhuman research
Nonhuman self-administration provides an opportunity to assess the
reinforcing properties of a drug. In many studies, infrahumans are given an
opportunity to emit a response that is followed by drµg delivery. If a drug maintains
responding it serves as a positive reinforcer. Nonhuman self-administration provides
a way of studying the mechanisms controlling behavior including an array of
physiological mechanisms and environmental variables, such as reinforcement
contingencies and stimulus control (Thompson & Boren, 1977). Thus, the study of
drugs as reinforcers offers insight into understanding basic mechanisms controlling
behavior.
Methylphenidate produces reinforcing effects as demonstrated by a number of
studies in which it is reliably self-administered by nonhumans. For example, Risner,
& Jones (1975) demonstrated that dogs would initiate and maintain responding
reinforced by MPH. Under conditions in which MPH was freely available, wherein
every response produced a drug injection, the subjects began to self-administer MPH
within one to six days after it became available. Numerous additional studies have
demonstrated that methylphenidate is self-administered at rates above saline in
infrahumans, thus it is an effective reinforcer (e.g., Aigner & Balster, 1979; Johanson
& Schuster, 1975).
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Human Research
Examining methylphenidate self-administration behaviors in nonhumans
provides us with a way of studying the mechanisms that control behavior in a
laboratory setting. However, it is important to also examine the conditions in which
MPH serves as a reinforcer and gains control over human behavior (e.g.,
Henningfield, Lukas, & Bigelow, 1986; Johanson & deWit, 1989). MPH produces
dose-related increases in participant-rated effects in non-drug abusing adult humans
on measures such as "euphoria" (Chait, 1994; Martin et al., 1971; Smith & Davis,
1977). However, it is necessary to examine both the reinforcing effects as well as the
subjective effects of MPH in human participants in order to improve the
understanding of the mechanism of drug action.
One way to assess the reinforcing effects of a substance in humans is through
a choice procedure (e.g., deWit & Johanson, 1987) wherein the participants'
preference for one of two substances is measured. During this procedure, participants
fust experience a sampling phase in which they are exposed to a drug and a placebo,
contained in separate color-coded capsules, under double-blind conditions on separate
days. In these double-blind conditions, neither the subject nor the experimenter is
aware of the contents of the capsules. Participants are typically told they are receiving
"Drug A" or "Drug B." They are instructed to note the color of the capsule and to try
to associate any drug effects with that color capsule. Participants are told that the
same drug will always be contained in the same color capsule. Following the
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sampling phase, the participants are given the opportunity to choose which drug (i.e.,
which colored capsule) they would like to administer.
There are only three published studies that have directly examined the
reinforcing effects of MPH in humans (Chait, 1994; Roehrs et al., 1999; Rush, et al.,
in press). Chait (1994) measured the subjective and reinforcing effects of
methylphenidate in 35 non-drug abusing human participants using a choice
procedure. Participants were administered MPH and placebo on alternating days.
Following this sampling phase was a choice day, wherein the participants could
choose between MPH (20-40 mg), placebo, or neither drug. Participants participated
in three choice days. The results indicated that out of 105 total choices across
participants, MPH was chosen 29 (27.6%) times, placebo was chosen 9 (8.6%) times,
and neither substance was chosen in 67 (63.8%) occasions. Conclusions regarding the
sources of variability that predict the choice of MPH cannot be drawn based solely on
an individual study. Nevertheless, the findings warrant a more comprehensive
assessment of the subjective and reinforcing effects of MPH, especially given its
widespread clinical use.
In the second study that examined the reinforcing effects of MPH (Roehrs et
al., 1999), researchers manipulated the sleep times of six healthy volunteers 21-30
years of age. During four sampling days, participants received 10 mg MPH or
placebo following four or eight hours in bed. On four separate choice days, after
spending four or eight hours in bed, participants chose their preferred capsule. The
results indicated that MPH was chosen significantly more after four hours in bed
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(88%) as compared to choices made following eight hours in bed (29%). The authors
suggest that the enhanced preference for MPH after four hours in bed is consistent
with studies showing that the reinforcing effects of a drug relate to current
environmental circumstances.
In the final study, Rush et al. (in press) assessed the reinforcing effects of
MPH (20-40 mg), d-amphetamine (10-20 mg), and placebo in eight healthy, non
drug-abusing, non-sleep-deprived adults using a modified progressive ratio schedule,
which are frequently used to assess the reinforcing effects of commonly abused
drugs. In the progressive ratio schedule used, participants had eight opportunities to
work on a computer task in order to earn eight capsules. These capsules each
contained 12.5% of the dose used in the sampling session. The number of mouse
clicks required to earn additional capsules doubled (e.g., 50, 100, 200, 400, 800,
1600, 3200, 6400). The dependent measure used was the break point, which is the last
ratio completed. Results indicated that the highest dose of MPH (40 mg) increased the
break-point values significantly above placebo, demonstrating that MPH functioned
as a reinforcer in these non-drug-abusing, non-sleep-deprived participants.
Through increased understanding of the reinforcing and participant-rated
effects of MPH, it may be possible to clarify the behavioral mechanisms of this drug
with respect to its clinical effects in children to whom it is prescribed for behavioral
difficulties. It is probable that drugs that cannot be differentiated from placebo are
less likely to be self-administered again by a subject, while drugs that are identified
(discriminated) as a stimulant have a higher chance of being self-administered by the
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subject (Foltin & Fischman, 1991). Similarly, it is often assumed that certain
subjective effects of drugs are related to their reinforcing effects, however, the exact
nature of this relationship may vary across participants and environmental settings. In
addition, the clinical effects of MPH may be associated with the subjective and
reinforcing effects of the drug as well. This relationship may also vary across
participants and environmental settings.
The reinforcing effects of a drug are typically associated with the drug's abuse
liability. However, the present study will explore an alternative to this
conceptualization that will result in a better understanding of the stimulus functions of
MPH. By examining the relationships among the subjective, reinforcing and clinical
effects, we can gain insight into the behavioral mechanisms of MPH in children
diagnosed with ADHD. An investigation of the relationship between these functions
can extend the present understanding of how a drug works.
Purpose of Present Study
Methylphenidate produces a wide array of clinical effects in children
diagnosed with ADHD. Yet, we do not know how these clinical effects are related to
the stimulus functions of MPH. It is not known if evidence of the clinical effects of
MPH can be used to predict the subjective and reinforcing effects of the drug.
Likewise, it is not certain whether information regarding the reinforcing and
subjective effects can be used to predict the clinical efficacy of MPH in children
diagnosed with ADHD.
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Methylphenidate has several stimulus functions, yet we do not know how
these functions relate to the behavioral effects seen in children diagnosed with ADHD
who are prescribed MPH. The present study examines (a) the extent to which MPH
exerts reinforcing effects determined by the reliable choice of active medication
versus placebo, (b) the extent to which MPH exerts subjective effects, and (c) the
extent to which the subjective and reinforcing effects are associated with one another
and with the clinical effects of MPH.

METHODS
Participants
Participants for this study included four males (ages 10-14) and one female
(aged 10). Participants were recruited through local physicians and psychologists,
recruitment flyers, and word ofmouth.
Participants were recruited on the basis oftwo criteria: (1) an established
diagnosis ofADHD, and (2) a history ofmethylphenidate use for behavior problems
associated with ADHD. The subject's parents, or one parent and another individual
with whom the child has significant contact, completed the Child Behavior Checklist
(Achenbach & Edelbrock, 1993; inclusionary criterion was an Attentional Problems
subscales T score� 65); Conners' Parent Rating Scale-48 (Conners, 1990;
inclusionary criterion was an Impulsive-Hyperactive Scale T score� 65). These
inclusionary criteria were used to corroborate the ADHD diagnostic status of
participants and to ensure a relatively homogeneous group. (See Table 1 for subject
demographics.)
In addition, all participants in the study had a prescription for immediate
release methylphenidate (Ritalin) for the treatment ofADHD. Subject 2 was
previously receiving sustained-release MPH due to poor treatment compliance;
however, his physician altered his dose to a comparable dosage ofMPH-IR for the
purposes ofthis study. Participants each had been receiving MPH treatment for at
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Table 1
Subject Demographics
CPRS-48
WISC
(Impulsive(Block Design
Hyperactive;
+ Vocab.)
Hyperactivity Scale)

Sex

Age

Height

Weight

Time
on
MPH

1

M

10

4'11"

85 lbs.

36mos.

10mg

T=69

T = 72
T = 92

IQ=91

2

M

14

5'7"

200 lbs. 60mos.

20mg

T=81

T=72
T = 86

IQ=68

3

M

10

NA

NA

36mos.

10mg

T=70

T = 76
T=83

IQ=83

4

M

14

5'2"

100 lbs.

84mos.

30mg

T=78

T=76
T = 76

IQ=126

5

F

10

5'2"

100 lbs. 12mos.

10mg

T=72

T = 87
T=99

IQ=106

Subject

Dose

CBCL
{Attention
Problems)
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least six months prior to selection for the study, so as to determine the probability of
any potential side effects. Due to the inclusion of MPH manipulation, each subject's
prescribing physician was contacted and the purpose and procedure of the study was
explained. On experimental days, participants experienced only one variation in their
typical daily medication regimen. This drug manipulation involved the child's late
afternoon dose and occurred in the laboratory setting. The child received his/her usual
maintenance dose during morning and noon administrations.
Participants were excluded from the study if (a) they were taking any other
type of psychoactive medication, (b) they exhibited any gross neurological, (c) if
there was any sensory or motor impairment, (d) they had a history of other significant
learning or psychiatric problems, and/or a known family history of diabetes. Nine of
the 14 children screened were excluded for various reasons. Three children were
excluded because they were receiving psychoactive medications in addition to MPH,
two were not currently receiving MPH treatment, one did not meet age requirements,
and two could not commit to the length of the present study.
Volunteers were directly compensated in two ways. Participants received
$1.00 for each session completed, plus an additional $10 bonus for completing all 13
sessions. In addition, during experimental sessions, participants received assistance
with outside homework assignments, and practiced basic academic skills.
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Location and Duration
LCABS
Participants reported to the Laboratory for Child and Adolescent Behavioral
Studies (LCABS), which is located in 1504 Wood Hall at Western Michigan
University. The screening session, medication administration and the completion of
self-report forms took place in LCABS. This is also where the subject received
compensation for participation.
Project Help
Behavioral observations took place in a classroom operated and staffed by
Project Help, a remedial education service project sponsored by the School
Psychology program and the Department of Psychology at WMU, located in 1509
Wood Hall. Project Help is an academic skills enrichment program which serves K12 students who are at-risk of academic failure and who may benefit from instruction
in basic skill areas such as reading, math, writing and spelling. This setting included
approximately ten students emolled in Project Help with their respective tutors.
Children emolled in this program receive one-to-one attention from the staff.
Participants in this study were not formally emolled in the tutorial program, thus did
not have an individual tutor. However, participants were seated at individual cubicles
and had access to a desk and a computer. Participants were engaged in various
academic tasks while in the Project Help facility.
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Parents/guardians were responsible for arranging transportation to and from
LCABS on 13 separate occasions. The screening session lasted approximately one
hour. Subsequent experimental sessions were conducted Monday through Thursday
beginning at approximately 4:00 p.m. and lasting until approximately 6:00 p.m.
Apparatus/Materials
Capsules
The subject's maintenance dose ofmethylphenidate and an inert placebo were
each packaged in opaque capsules (size 0 1) to ensure that the enclosed substance was
unknown to the subject and to the researcher. The capsules were placed in separate
bottles labeled as "Bottle A" and "Bottle B" with the methylphenidate being one
letter (e.g., "A") and the placebo being the other (e.g., "B"). The capsule letter
assignments were varied across participants. However, the participants were informed
that the same lettered capsule always contained the same thing.
Colored Wristbands
The participants received a wristband that was labeled with the letter ofthe
capsule he/she received that day. This wristband was to remind the participants which
letter capsule they received, so that they could associate the effects ofthat capsule
with the appropriate letter.
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Cueing Tape
A tape recording that contains cues for the beginning of 30-second intervals
was used in direct observations. The tape said, "Begin l " and then 30-seconds later,
"Begin 2." Observers used a tape recorder and headphones when using this tape while
recording observations.
Dependent Measures
Drug Choice Behavior
Participants first sampled two capsules containing either methylphenidate or
placebo, which were contained in capsules labeled with different letters. In
subsequent discrete choice trials, the subjects were presented with the labeled
capsules and chose the substance they preferred (i.e., "Pill A", "Pill B" or neither).
The use of a "Neither" option was included to replicate prior examinations of the
reinforcing effects of MPH (Chait, 1994) and to provide a more reliable measure of
the reinforcing efficacy of the chosen substance (Spiga & Roache, 1997). The number
of times one substance was chosen over the other served as an indicator of its relative
reinforcing effects (deWit, 1991). The drug choice was recorded on the subject's
daily score sheet. This choice procedure is a technique that has been used to measure
the reinforcing effects of a number of different drugs, in a range of contexts and with
various subject populations (Johanson & deWit, 1989; deWit & Griffiths, 1991;
Foltin & Fischman, 1991).
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Participant-Rated Effects
In order to assess the participant-rated effects of MPH in children diagnosed
with ADHD, the participants completed various self-report measures. Subjective
effects are important because of their potential relationship to drug choice (Jasinski &
Henningfield, 1989). Children may experience a variety of mood and physiological
changes as a result of stimulant medication. The participant-rated effects are
important in that they may be useful in predicting reinforcing and clinical efficacy of
MPH. The subjective ratings were assessed pre-drug administration, and 1 ½-2 hours
post-drug administration. The following self-report scales were used to evaluate these
effects.
How I Feel Questionnaire
This is a 28-item questionnaire adapted from the van Kammen-Murphy Mood
Scale (van Kammen & Murphy, 1975). Items are rated on a 4-point scale (0 = Not at
all, 1 = A little, 2 = Some, 3 = A lot). This adapted scale has been used with children
to measure the subjective effects produced by caffeine (Elkins et al., 1981) and d
amphetamine (Rapoport et al, 1980).
Profile of Mood States {POMS)
A short form of the POMS was used to assess mood and affective state. This
version consists of 37-items that are rated on a 5-point scale (0 = Not at all, 1 = A
little, 2 = Moderately, 3 = Quite a bit, 4 = Extremely). Compared to the original 65-
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item scale (McNair et al., 1971), the shortened version has been shown to have
adequate psychometric properties (Shacham, 1983). This scale has been used to
assess the effects of stimulants in children (Walker et al., 1988). Six scales are
derived from the 37 items: (1) anger/hostility, (2) confusion/bewilderment, (3)
depression/dejection, (4) fatigue/inertia, (5) tension/anxiety, and (6) vigor/activity.
Subjective Effects Rating Scale (SERS)
This is a 22-item scale developed by Kollins et al. (1998) to assess the
participant-rated effects of methylphenidate and other stimulant medication in
children and adolescents. Items from the questionnaire are rated on a 4-point scale
(O= Not at all, 1=A little, 2=Some, 3=A lot). Items on the SERS were derived from
three sources. First, stimulant-appropriate items from the Addiction Research Center
Inventory (ARCI; Martin et al., 1971) were selected and changed to an age
appropriate reading level. Secondly, items were selected from the Side Effects Rating
Scale (Barkley, 1991). Lastly, items were selected based on discussions with
clinicians experienced in working with children diagnosed with ADHD.
Visual Analog Scale (VAS)
The VAS consisted of ten 100-mm horizontal lines each labeled with a
different item. Each scale was presented individually. Participants were instructed to
rate each item on the basis of how they felt at the present time. Each VAS scale was
anchored with "not at all" at the left-most extreme, and "very much" at the right-most

extreme. Participants were instructed to place a mark on each line indicating how they
felt at the moment. The items rated included (a) like drug, (b) energetic, (c) sleepy,
(d) friendly, (e) restless, (f) nervous, (g) hungry, (h) excited, (i) happy, and (i) feel
like talking.
Direct Behavioral Observations
An independent observer began direct observations 45 minutes after the pill
ingestion to ensure peak behavioral drug effects, and observed for three 15-minute
intervals. Participants were observed for 15 minutes while they were engaged in
academic work. Using the cueing tape, every 30 seconds the observer checked on the
coding sheet whether any of the five behavior categories were observed. Once a
behavior was checked during an interval, it could not be checked again until the next
interval. The first and third observation periods were conducted in Project Help, while
the second period was conducted during a break in order to observe the child during
social situations.
During the direct observation periods conducted in Project Help, children
completed the in-seat academic work assigned by the research assistant. Data were
collected using the ADHD Behavior Coding System developed by Barkley (1990). In
this system, the child was observed during the performance of independent academic
work (the Restricted Academic Situation; RAS). Observers recorded the occurrences
of (a) off-task behavior, (b) fidgetiness, (c) vocalizing, (d) playing with objects, and
(e) out of seat behavior.
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During the social situation observations, observers recorded behavioral
observations that occurred during a 15-minute break from academic work. During this
break, children were allowed to leave their assigned seat and engage in social
activities with other children in the Project Help program. The types of social
activities included (a) playing computer games, (b) listening to music, (c) visiting the
vending machines, and (d) playing outdoors. Data were collected using the Social
Situations Behavior Coding Form (adapted from Pelham, Vodde-Hamilton, Murphy,
Greenstein and Vallano, 1991). Observers recorded the occurrences of (a) positive
peer interactions, (b) conduct problems, (c) noncompliance, (d) interrupting, and (e)
negative verbalizations.
The observers were advanced undergraduate psychology students. The
researcher trained the observers using instructions adapted from Barkley (1990), role
playing, and by modeling appropriate coding using videotapes of children in school
and social situations. Observers were trained using the videotapes until 0.90
agreement was achieved. This training was completed in an average of four sessions
lasting one-half hour each. During the present study, observers were situated in the
room such that they avoided direct eye contact with, and were distanced from, the
target child by approximately two cubicles, while allowing for clear determination of
task-related attention. Observers were blind to the contents of the medication
capsules.
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Interobserver Agreement
A second independent observer collected data using the Restricted Academic
Situation and Social Situations behavioral coding forms during a minimum of 25% of
the direct observations across participants. Interobserver agreement for all ten
categories was calculated by dividing the number of agreements by the number of
agreements and disagreements and multiplying by 100. The interobserver agreement
was calculated separately for each category used in the behavioral observations.
Teacher Ratings
In-class observations correlate highly with teaching ratings of ADHD
symptoms (Barkley, 1990). Therefore to evaluate reliability, the same research
assistant completed the Conners' Teacher Rating Scale-28 (CTRS-28; Conners, 1990)
every session, 1.5-2 hours after the subject received his/her capsule. The CTRS-28 is
effective in assessing stimulant drug effects and other treatment effects, when the
convenience of completion of the scale is paramount (Barkley et al., 1988).
Procedures
Screening Session
The first session was a screening session wherein the child's parent completed
the CBCL (Achenbach & Edelbrock, 1993) and the CPRS-48 (Conners, 1990).
Parents were also given an additional copy of these forms to be completed by another
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adult with whom the child has significant contact. In the first session the child was
administered a short form of the Wechsler Intelligence Scale for Children (3rd ed.:
WISC-III; Block Design and Vocabulary subtests; Wechsler, 1991), to screen for
intellectual functioning. If the children met criteria for the experiment, parents were
asked to provide consent to contact the child's physician to assure that the protocol
was in the best interest of the child and to provide a prescription for MPH and
placebos. The placebo used was dextrose, so all participants were screened for
diabetes through the parent interview on medical history. The same local pharmacist
at Sindecuse Health Center at Western Michigan University filled all prescriptions.
The pharmacist encapsulated the active medication and the placebo in capsules that
were identical in appearance, which were placed in separate bottles labeled with
different letters. All filled prescriptions were paid for and picked up by the researcher
at Sindecuse Health Center.
Throughout the remaining 12 sessions, participants arrived at LCABS
between 3:45-4:00 p.m. A multiple drug free choice procedure was used to assess the
reinforcing effects of MPH. This design consisted of six sampling sessions designed
to provide participants with experience with the effects of the two drug conditions,
MPH and placebo, on the basis of which they subsequently chose their preferred
substance. The choice phase consisted of six choice sessions wherein under double
blind conditions, participants selected MPH, placebo, or neither substance. Details of
the sampling and choice sessions are as follows.
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Sampling Sessions
There were six sampling sessions, which occurred on Mondays and Tuesdays
for three weeks. On the first sampling day, upon arriving at LCABS, participants
completed the participant-rated effects questionnaires. After completing the
questionnaires, participants received either placebo or MPH in a capsule labeled "Pill
A" or "Pill B." In the second sampling session, participants received the other
substance in a capsule of a different letter. Participants also received a wristband
labeled with the same letter as the pill administered to help them remember what
capsule they received that day. Participants were instructed to associate the effects of
the capsule with the letter. Capsule letter assignments varied across participants.
Participants were informed that the same letter capsule would always contain the
same thing (e.g., "real" medication or "pretend" medication). The order in which
placebo and MPH were scheduled in the sampling sessions was counterbalanced
across subjects and within-subjects across weeks. Drug administration was double
blind, and the experimenter and the observers were unaware of the contents of the
capsules.
After receiving the capsule, the subject was escorted across the hall to the
Project Help facility. While in Project Help, the subject was seated at his/her assigned
desk and worked on various academic tasks. Participants received assistance with
homework assignments from school, played computer games, and worked on math
and spelling worksheets provided by the researcher.
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An independent observer began direct behavioral observations 45 minutes
after the ingestion of the capsule (approximately 4:45 p.m.). During this time the
participant was directed to work on various math sheets and was observed for 15
minutes. Project Help had a scheduled break from 5:00-5:15 p.m. During this time,
research participants also took a break, and were encouraged to participate in the
break-time activities. During the break, the observer recorded behaviors using the
Social Situations Behavioral Coding Form.
Following these direct behavioral observations, between 1 ½ -2 hours after the
ingestion of the capsule, a research assistant completed the CTRS-28 rating form.
Two hours after the ingestion of the capsule (approximately 5:45 p.m.-6:00
p.m.), the subject met with the researcher in the conference room in LCABS to
complete the participant-rated effects questionnaires. After the completion of the
questionnaires, the subject received monetary compensation from the researcher and
was provided with verbal praise for his/her participation.
Choice Sessions
The choice phase provided the primary dependent measure, the number of
occasions on which one substance was chosen over another. There were six choice
sessions which occurred on Wednesdays and Thursdays for three weeks. In the choice
sessions, upon arriving at LCABS, participants completed the participant-rated effects
questionnaires. Following the completion of the questionnaires, participants were
presented with three cups: one with "Pill A," one with "Pill B," and an empty cup
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labeled "C." The participant chose one of three options: (1) to ingest "Pill A," (2) to
ingest "Pill B," or (3) to take neither capsule. The child was presented with a letter
matched wristband (with "Neither" being labeled "C"). Following the choice
procedure, the participant was escorted to Project Help. The procedures for collecting
direct behavioral observations, teacher ratings and participant-rated effects were the
same as in the sampling sessions.
Integrity of Independent Variable
The independent variable in this experiment involved the pharmacological
manipulations of drug type (i.e., MPH or placebo). In order to ensure that the
independent variable contacted the participant's behavior and was consistently
administered, there was a data-recording checklist. On this chart, the letter of the pill
administered and the time of administration was recorded. In addition, after the
behavioral observations were completed, the observer initialed the data-recording
sheets. Likewise, when the participant-rated effects were collected, they were
checked on the recording form. All of the participant's data were labeled with his/her
identification number and stored in a binder kept in a locked cabinet in LCABS.

RESULTS
Reinforcing Effects
The results of the choice sessions were analyzed by examining the percentage
of MPH choices per subject (Figure 1). Overall, out of 30 total choices across
participants (six choices each), MPH was chosen 18 times (60%), placebo and neither
were each chosen six times (20%).

100.0
90.0
CJ')
80.0
Q)
u
·a 70.0
60.0
50.0
40.0
Q)
u 30.0
Q)
a.. 20.0
10.0
0.0

60.0

MPH

20.0

20.0

Placebo

Neither

Pill Choice
Figure 1. Reinforcing Effects of MPH Across Participants.
According to the criteria used by Chait (1994), Participants 2, 4 and 5 were
classified as "MPH choosers." Participant 2 chose MPH 4/6 (67%) and Placebo 2/6
36
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(33%). Participants 4 and 5 both chose MPH 5/6 times (83%) and Neither one time
(16%).
Participants 1 and 3 did not have reliable choice patterns and were classified
as "non-choosers." Participant 1 chose MPH 3/6 times (50%), Placebo 2/6 times
(33%) and Neither 1/6 times (16%). Participant 3 chose MPH 1/6 times (16%),
Placebo 2/6 times (33%) and Neither 3/6 times (50%) (Figure 2).

■ Subject 1
■ SubJect 2
□ Subject 3
SubJeCt 4
□ SubJect 5

6
5
Q)

·o
Q)

4
3
2
1
0
MPH

Placebo

Neither

Figure 2. The Choices of MPH, Placebo, and Neither for Each Participant to
Demonstrate Relative Reinforcing Effects.
MPH choice was also plotted as a function of dose across participants (Figure
3), wherein the percentage of choices made at Placebo/Neither, 10 mg, 20 mg, and 30
mg were plotted. Out of the 30 choice opportunities in which Placebo and Neither
were available, 12 choices (40%) were for Placebo or Neither. Out of the 18 choice
opportunities in which 10 mg of MPH was available, MPH was selected nine times
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Figure 3. MPH Choice as a Function of Dose Across Participants With Six Choices
per Participant. (The numbers in parentheses represent the number of
choices across participants in which a given option was available.)
(50%). Out of the six choice opportunities in which 20 mg of MPH was available,
MPH was selected four times (66.7%). Out of the six choice opportunities in which
30 mg of MPH was available, MPH was selected five times (83.3 %). This indicates
that MPH choice increased as a function of dose.
Clinical Effects
Behavioral observations and the number of math problems attempted and
correctly completed were examined under MPH and placebo conditions. Initial t-tests
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on the categories used for behavioral observations and academic performance yielded
no significant results between MPH and the No Drug condition (Placebo/Neither). In
addition, there were no significant differences obtained between sampling and choice
sessions. The results from the behavioral observations using the Restricted Academic
Situations coding form are shown in Table 2.
The results from the Social Situations observations are not presented since the
participants did not typically engage in activities that yielded any behaviors that met
criteria for the categories used during observations.
Given the lack of significant differences, examining the interactions between
the clinical effects, reinforcing effects, and subjective effects of MPH was not
possible.
Participant-Rated Effects
Subjective effect questionnaire data were analyzed for each participant. In
order to examine the participant rated effects, the change from baseline (post-drug
administration scores-pre-drug administration scores) was computed for each item,
and the absolute values for the change scores were averaged for each questionnaire.
The differences between change scores obtained on MPH days and No Drug (i.e.,
Placebo or Neither) days were computed. Items that differed from the average by one
standard deviation were considered to be meaningful changes.
Table 3 shows the results from the individual-subject analyses. The patterns of
responding on the participant-rated effects questionnaires were inconsistent across

Table 2
Percentage of Intervals in Which Target Behaviors Were Observed
Using the Restricted Academic Situations Coding Form Averaged Across Sampling and Choice Sessions*
Subject 1

Subject 3

Subject 2

Subject 4

Subject 5

MPH

No Drug

MPH

No Drug

MPH

No Drug

MPH

No Drug

MPH

No Drug

Of task

36.6

55.5

51.4

49

67.5

78.8

63.8

83.3

48.9

53.3

Fidgety

65.8

85.2

20.2

18.3

80.5

86.7

77.6

50.0

61.25

60.0

Vocalizing

2.5

1.7

0

0.3

3.6

23.8

4.8

2.7

8.9

083

Playing
w/objects

3.6

3.8

7.4

9.7

3.9

8.6

19.5

27.2

8.9

21.3

Out of seat

5.5

5.2

8

4.0

20

15.7

6.9

11.6

4.8

9.6

* No significant differences between the MPH condition and the No Drug (Neither/Placebo) conditions were observed.
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Table 3
Participant-Rated Effects
Subject
1

Subject
2

Subject
3

Subject

4

Subject
5

POMS Subscales
Tension
Confusion
Vigor

-!,

t

t

-!,
-!,

How I Feel Items
Trouble keeping mind on things
Restless
"Funny"
A lot of energy
Tired and slow
Weird, "freaky"
No one wants to help me
Unusual thoughts
Unhappy
Doing a pretty good job
Something good will happen
Mad
Friendly
Happy

-!,
-!,

-!,

t

-!,

-!,

t

-!,

t
t

-!,
-!,

t

t

t
t

-!,

t
t

SERS
Feel like talking
Can concentrate
Like joking
Hungry
Focused on work
Popular
Get along with others
Daydreamed
Heart beating fast
Worked well
Excited

-!,

t

-!,
-!,

t

-!,
-!,

t

-!,
-!,

t
-!,
-!,
-!,

t
t

t
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Table 3-Continued

Subject
1

Subject
2

Subject
3

Subject
4

t

t

Subject
5

Visual Analog Scales
Energetic
Excited
Like Drug
Sleepy
Restless

Note: Questionnaires were averaged across sampling and choice sessions for
individual subjects. Arrows indicate a significant deviation from the average change
across questionnaires. The direction of the arrows indicates the effect of MPH relative
to the "no drug" condition (i.e., placebo or neither). Dashes indicate no significant
differences.
subjects. Table 3 shows differences across participants with respect to the number of
items significantly affected.
For example, in the present study, relative to placebo, MPH produced
increased ratings of "feel funny," and "tired/slow" in Participant 1, and decreased
ratings of "tension," "restless," "energetic," and "feel like talking". MPH also
increased ratings of "can concentrate" and decreased ratings of "trouble keeping mind
on things."
Participant 2 had a variable pattern of responding in which, relative to
placebo, MPH produced decreases in "popular," "energetic," and "excited". MPH
was associated with increased ratings of "confusion," "having unusual thoughts," and
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"no one wants to help me." MPH also increased ratings of "focused on work," but
decreased ratings of "can concentrate."
Relative to changes seen with placebo, MPH produced increased ratings of
"like drug," "doing a good job" and "tension" in Participant 3. Yet, MPH produced
decreased ratings of "daydreamed," "popular," "unhappy," and "having trouble
keeping mind on things."
MPH produced increased ratings of "like drug," "excited," "worked well,"
and "something good will happen today" in Participant 4 when compared to placebo.
MPH also decreased ratings of "restless" and "vigor."
When compared to placebo, MPH produced increases in "friendly," "doing a
good job," "happy," "feel like talking," and "heart is beating fast" in Participant 5.
MPH decreased ratings of "sleepy," "restless," "mad," "tired/slow," and "tension."

DISCUSSION
The present study demonstrated that MPH served as a reinforcer for three out
. of five participants, and produced idiosyncratic patterns of subjective effects. Before
discussing implications, several limitations are warranted.
These limitations include the small sample size, such that only five children
were included. The results obtained may not be typical since this small sample may
not be a representative population. Previous studies examining the reinforcing effects
of MPH in adults used larger sample sizes (N=35, Chait, 1994; N=6, Roehrs, et al.,
1999; and N=8 Rush et al., in press). Thus, it would be beneficial to replicate these
findings with a larger subject population.
In addition, the choice procedure may not be a valid measure of abuse
potential upon considering the possibility of a child who chooses to take medication
(e.g., MPH) because the consequences are better academic performance and
improved social interactions, yet there is a lack of clear euphorogenic results.
However, this substance still has abuse potential in adults, as demonstrated by
reinforcing, subjective and discriminative stimulus effects. This may call for an
examination of the validity of the choice procedure as a measure of abuse liability. In
fact, the strong preference for a drug in an experimental context may not indicate that
a particular research participant (or an individual sharing similar qualities) will abuse
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that substance given the many environmental factors that contribute to drug use
(Johanson & deWit, 1989).
Another weakness of the present study surrounds the collection of subjective
effect data. In the present study, the subjective effects were evaluated two hours post
drug administration. Previous studies examining the subjective effects of drugs have
collected participant-rated effects pre-ingestion, one, three, and six hours post
ingestion (Chait, 1994; Johanson & Uhlenhuth, 1980). In the present study, collecting
participant-rated effects at more than one time period post-drug administration could
have been used to determine a time-course function of MPH. In addition to the
collection of data, the reading level of the children may have affected the manner in
which the subjective effects were evaluated, such that the participants may not have
fully understood the items on the questionnaires. Thus, the lack of reading
comprehension may have contributed to within-subject variability on the measures of
subjective effects.
Lastly, relevant behavior changes were not observed under both drug and
placebo conditions. The setting used for the behavioral observations may have caused
the lack of clinical effects. In the Project Help facility, enrolled students receive one
to-one attention from their respective tutors. Tutors are instructed to prompt students
to attend to their assignment when they are off-task. Students have the opportunity to
earn rewards for remaining on task. Participants in the present study did not have
these contingencies in place. Thus, it was not possible to compare the behavior of the
participants to non-diagnosed peers. In addition, during social situations, the
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participants, and the enrolled students, engaged in activities that did not involve
interaction with others, (e.g., computer games at their cubicles). Therefore it was not
possible to observe the effects of MPH on the social skills of the participants. The
prevailing contingencies in the Project Help facility may have masked any behavioral
changes. Therefore, the present study should be replicated in a different setting that
may yield clinically relevant behavioral changes. However, despite these limitations,
given the widespread clinical use of MPH, the present findings appear to warrant a
more comprehensive assessment of the subjective and reinforcing effects of MPH,
and how these effects are related to the clinical effects.
Our study demonstrates that MPH functioned as a reinforcer in three out of
five participants according to the criteria used by Chait (1994). The demonstration of
the reinforcing effects of MPH in children diagnosed with ADHD has several
important implications. First of all, the present study demonstrates that a drug used to
treat a clinical disorder (i.e., ADHD) functions as a reinforcer in a group of
individuals diagnosed with that disorder. This has implications for the practice of
clinical psychopharmacology. For example, if MPH functions as a reinforcer that
sustains self-administration behavior, this could be utilized therapeutically to the
extent that the reinforcing efficacy of the drug may predict the degree to which a
patient complies with medication treatment (Henningfield et al., 1986). If the stimulus
functions are related to the clinical effects of MPH, one might be able to predict
whether MPH will be successful in treating ADHD symptomatology.
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Although drug self-administration has been used to predict abuse potential, it
is possible that the reinforcing effects observed in the present study do not necessarily
suggest abuse. Substance abuse is defined as a maladaptive pattern of substance use,
which leads to significant impairment arising from social, vocational, legal or family
problems (DSM-IV; APA, 1994). The DSM-IV defines substance dependence as a
pattern of repeated self-administration leading to clinically significant impairment
associated with difficulty controlling the substance-taking behavior, withdrawal and
tolerance (APA, 1994). Both substance dependence and abuse are associated with
compulsive drug seeking and drug-taking behavior
The reinforcing effects of a substance describe the relationship between the
behavior (i.e., drug taking) and the consequences of that behavior (i.e., drug effect).
Drug self-administration is a primary indicator of drug reinforcement-the choice
behavior directly produces administration of the drug (deWit & Johanson, 1987).
Reinforcement is said to occur when the presentation of the reinforcing stimulus (i.e.,
drug) increases the probability (or frequency) of the behavior that presentation of the
stimulus is contingent upon. This differs from the "abuse liability" of a substance,
which refers to the likelihood that its use will result in drug abuse and/or dependence
(Bozarth, 1987).
It is within reason to suggest that individuals may "like" a medication
perceived as being "helpful" without suggesting that they are abusing it. For example,
in the present study participants were asked under double blind conditions to provide
reasons for choosing the option they did during the choice sessions (e.g., Pill A, Pill B
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or Neither). Participants were also asked to comment on what they believed the pill to
be. Following the completion of the study, once the blind was broken, two-thirds of
the MPH-choosers (Participants 2 and 4), and 1 MPH-non-chooser (Participant 1)
correctly identified which pill was MPH. The anecdotal subject comments suggested
that children chose MPH (e.g., "Pill A" or "Pill B") when they "needed to calm
down" or wanted "to be able to concentrate." Participant 1 reported that he chose
Placebo or Neither when he believed he was "having a good day." These explanations
may not be indicative of "abuse," yet these patterns of self-administration becomes
"abuse" when MPH is ingested improperly (e.g., snorted or injected), administered in
amounts that exceed what was prescribed, or is used outside the scope of medical
authority by those for whom it is not prescribed.
A recent report by the Drug Enforcement Administration (DEA) suggested
that MPH has a high abuse potential, and is associated with diversion and trafficking
to an extent similar to other pharmaceutical Schedule II substances (Drug
Enforcement Administration, 2000). The diversion of MPH has been identified by
drug thefts, illegal sales and prescription forgeries (Drug Enforcement
Administration, 2000). However, unlike other Schedule II drugs, MPH is prescribed
predominately to children. Thus, information from parents, schools, physicians,
adolescent treatment centers, poison control centers, and law enforcement data
suggest that adolescents who are using this drug illicitly obtain it from individuals
that have been prescribed this drug for the treatment of ADHD (DEA, 2000). For
example, one recent survey of children and adolescents who had been prescribed
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MPH revealed that nearly one in five had been approached to sell, give away or trade
their medication at least once in the past five years (Musser, Ahmann, Mundt, Broste,
& Mueller-Rizner, 1998).
Because of the increased availability of MPH, resulting from a 800% increase
in MPH production and sales from 1990-1999, it is imperative to continue to examine
the behavioral pharmacological profile and abuse potential in children and
adolescents.
The variable patterns of responding in the present study make it difficult to
determine what accounts for the reinforcing effects of MPH. Choice behavior in this
and other contexts in which MPH is used is likely to be influenced by non
pharmacological factors such as differential attention from peers, teachers, etc.
Biological, environmental and psychological factors, including drug availability and
socio-cultural variables may all influence drug choice behavior. (For review see
Altmann et al., 1996). For example, peer relations play a significant role in the
initiation and escalation of substance use by increasing access to substances,
generating pressure and modeling or reinforcing maladaptive coping efforts (Bates &
Labouvie, 1995).
In addition to behavioral, psychological and environmental influences on
choice behavior, Volkow and colleagues (1999a, 1999b) have demonstrated that the
reinforcing effects of MPH are associated with increases in brain dopamine and
occupancy ofD2 receptors. Results indicate that there is a significant relationship
between increases in brain dopamine in response to MPH and the subjective ratings
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of "high" and "rush," with subjects having the greatest increases in DA being those
who perceived the most intense high. Likewise, subjects for whom MPH did not
increase dopamine did not perceive a drug related high. Thus, the differences between
subjects in the rate of DA release contributes to the intersubject variability in
response to MPH and may influence drug choice behavior.
There are several participant characteristics that may explain the intersubject
variability with respect to choice. First, the age of the participants may have affected
the reinforcing effects of MPH. Of the three MPH-choosers, two (Participants 2 and
4) were aged 14, while two of the non-choosers (Participants 1 and 3) were both aged
10. Participant 5, who was classified as a MPH-chooser, was also 10 years old, yet
she was the only female participant. This raises the possibility of gender related
differences in the reinforcing effects of MPH.
Another possible explanation for the variable pattern of reinforcing effects
surrounds the length of time on medication. Participants classified as MPH-choosers
had been exposed to MPH treatment for an average of 52 months as compared to the
non-choosers who had been receiving MPH for an average of 36 months. The two
male MPH choosers had a longer treatment history than the other participants ( 60
months and 84 months, respectively). Thus, the amount of exposure to MPH may
have contributed to the reinforcing effects of MPH.
The dose of MPH may have also contributed to the reinforcing effects. Two of
the MPH-choosers were also receiving the highest doses of MPH. Participant 2, who
chose MPH four out of six times, was receiving 20 mg of MPH. Participant 4, who
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selected MPH five out of six times, was receiving 30 mg of MPH. Thus, the
reinforcing effects of MPH may increase in a dose-related manner.
There are several possible explanations for the variable choice patterns seen
across participants in the present study, thus it is difficult to determine the factors that
account for the reinforcing effects of MPH. Nevertheless, the results of the present
study with respect to the reliable selection of a drug that has been demonstrated to
have abuse potential, along with reports from the DEA should underscore the need for
additional research that assesses the reinforcing effects of MPH in humans.
In addition to investigating the reinforcing effects of MPH, the present study
examined responses on a series of participant rated effects questionnaires. The
patterns of responding obtained from the children in this study were inconsistent with
the patterns of responding in adult humans. In normal adult humans, MPH produces
increases in ratings on items such as (a) "arousal," (b) "vigor," (c) "stimulated," (d)
"high," (e) "talkative," and (f) "euphoric," while reducing ratings on items of
"depression" and "fatigue" (e.g., Rush et al., 1998). In a sample of cocaine-dependent
adults, MPH increased subjective ratings of a "dysphoric" nature, such as (a)
"anxiety," (b) "depression," (c) "anger," and (d) "dysphoria" (Roache et al., 2000).
Yet, the responses on the participant-rated effects questionnaires among the children
in the present study were idiosyncratic. This pattern of idiosyncratic responding may
provide additional evidence for a developmental difference in the ability to
subjectively report drug effects.
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For example, previous studies examining the effects of caffeine and d
amphetamine have demonstrated discrepancies in the subjective ratings of adults and
children (see Rapoport, 1982/1983 for review). In a series of studies examining the
effects of caffeine in grade school children, subjective reports of side effects or mood
alterations were more drug-sensitive for adults as compared to the children (Elkins et
al., 1981; Rapoport, et al., 1981). Whether the children actually experienced fewer
subjective effects, or simply were poor reporters is unknown. A similar age difference
was found in a comparison of ct-amphetamine effects between children and adults,
wherein subjective ratings were more sensitive in detecting stimulant placebo
differences for adults while objective measures were more successful for children
(Rapoport et al., 1980).
There are several explanations for the variable patterns of responding on the
participant-rated effects questionnaires. First of all, the children may lack the verbal
repertoire necessary to accurately describe drug effects. In addition, children may not
have the reinforcement history or training in identifying subjective drug effects. Also,
the variable response patterns may be a result of the combination of the inability to
accurately verbalize subjective experiences and the lack of reinforcement history for
providing verbal labels for these subjective effects. Thus, research on the
developmental pathways of the participant-rated effects of drugs is needed.
Despite the rates of MPH use in children, only a few studies have assessed
children's perceptions of the effects of stimulant medications and how children feel
about receiving such treatment (Baxley, Turner, & Greenwold, 1978; Renker &
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Whalen, 1980; Cohen & Thompson, 1982). In general, these studies have
demonstrated that children are generally knowledgeable about the perceived function
oftheir medication, but are uncertain oftheir feelings surrounding taking the
medication. Many students report disliking their stimulant medication, although they
state that it is beneficial. Because a child's dissatisfaction with stimulant medication
may have significant implications for compliance (e.g., Brown, Borden, &
Clingerman, 1985; Brown, Borden, Wynne & Spunt, 1987) it seems important to
assess the general feelings, knowledge and attitudes ofchildren diagnosed with
ADHD who are being treated with stimulant medication.
The literature in customer satisfaction and treatment efficacy is rather limited,
thus, although the patterns ofresponding on the participant-rated effects
questionnaires in the present study were inconsistent, these subjective effects can
provide valuable information in the monitoring ofMPH effects in children for whom
it is prescribed. The participant-rated effects can provide information regarding the
child's attitudes, moods and feelings associated with the drug. Ifa child has negative
attitudes, moods and feelings surrounding the administration ofMPH, he/she may be
less likely to comply with taking medication. Thus, assessing the subjective effects of
MPH may provide valuable information regarding a child's adherence to stimulant
treatment.
The present study began to address the extent to which MPH exerts
reinforcing effects and participant-rated effects in children diagnosed with ADHD, as
well as the extent to which the participant-rated effects and the reinforcing effects are
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associated with one another and with the clinical effects of MPH. Further
examination of the relationships among these stimulus functions and the clinical
effects of MPH may provide valuable information regarding the behavioral
pharmacological profile of this drug. This information may be used to not only assess
the abuse potential of MPH, but perhaps more importantly to determine the likelihood
of treatment compliance and treatment satisfaction.

Appendix A
Protocol Clearance From the Human Subjects
Institutional Review Board
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